22R Stock Overview
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ContraFect Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.56 |
| 52 Week High | US$270.48 |
| 52 Week Low | US$4.00 |
| Beta | 0.43 |
| 1 Month Change | 0% |
| 3 Month Change | -5.00% |
| 1 Year Change | -97.97% |
| 3 Year Change | -98.86% |
| 5 Year Change | -99.63% |
| Change since IPO | -99.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22R | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | 1.8% |
| 1Y | -98.0% | -22.4% | 2.2% |
Return vs Industry: 22R underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 22R underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 22R volatility | |
|---|---|
| 22R Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 22R's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 22R's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | Roger Pomerantz | www.contrafect.com |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
ContraFect Corporation Fundamentals Summary
| 22R fundamental statistics | |
|---|---|
| Market cap | €2.16m |
| Earnings (TTM) | -€60.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 22R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22R income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$65.15m |
| Earnings | -US$65.15m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -41.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 22R perform over the long term?
See historical performance and comparison